Book a Demo

Laboratory evaluation of twelve portable devices for medicine quality screening



Background Post/market surveillance is a key regulatory function to prevent substandard and falsified (SF) medicines from being consumed by patients. Field deployable technologies offer the potential for rapid objective screening for SF medicines. Methods and findings We evaluated twelve devices: three near infrared spectrometers (MicroPHAZIR RX, NIR/S/G1, Neospectra 2.5), two Raman spectrometers (Progeny, TruScan RM), one mid/infrared spectrometer (4500a), one disposable colorimetric assay (Paper Analytical Devices, PAD), one disposable immunoassay (Rapid Diagnostic Test, RDT), one portable liquid chromatograph (C/Vue), one microfluidic system (PharmaChk), one mass spectrometer (QDa), and one thin layer chromatography kit (GPHF/Minilab). Each device was tested with a series of field collected medicines (FCM) along with simulated medicines (SIM) formulated in a laboratory. The FCM and SIM ranged from samples with good quality active pharmaceutical ingredient (API) concentrations, reduced concentrations of API (80% and 50% of the API), no API, and the wrong API. All the devices had high sensitivities (91.5 to 100.0%) detecting medicines with no API or the wrong API. However, the sensitivities of each device towards samples with 50% and 80% API varied greatly, from 0% to 100%. The infrared and Raman spectrometers had variable sensitivities for detecting samples with 50% and 80% API (from 5.6% to 50.0%). The devices with the ability to quantitate API (C/Vue, PharmaChk, QDa) had sensitivities ranging from 91.7% to 100% to detect all poor quality samples. The specificity was lower for the quantitative C/Vue, PharmaChk, & QDa (50.0% to 91.7%) than for all the other devices in this study (95.5% to 100%). Conclusions The twelve devices evaluated could detect medicines with the wrong or none of the APIs, consistent with falsified medicines, with high accuracy. However, API quantitation to detect formulations similar to those commonly found in substandards proved more difficult, requiring further technological innovation.

Published in: 
Research Gate
Date of Publication: 
September 1, 2021
Stephen Zambrzycki / Celine Caillet /Serena Vickers /Marcos Bouza/David V. Donndelinger /Laura Geben /Matthew Bernier /Paul Newton /Facundo Martin Fernandez
Medical University of South Carolina / WorldWide Antimalarial Resistance Network (WWARN) /University of Oxford / Georgia Institute of Technology / Vanderbilt University / Ohio State University
Read the Article

Ready to Streamline analysis processes for your business ?

See NeoSpectra in action and learn how it can enhance your analysis workflows. Complete the form to request a demo and we’ll be glad to guide you through its unique features.

Contact us
No items found.